COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Islet Transplantation in Type 1 Diabetic Recipients of Kidney Transplants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00288977
Recruitment Status : Completed
First Posted : February 9, 2006
Last Update Posted : March 16, 2017
Joslin Diabetes Center
Information provided by (Responsible Party):
Martha Pavlakis, Beth Israel Deaconess Medical Center

Brief Summary:
Study hypothesis is that we can reproduce results of islet transplantation in type one diabetics in patients with a kidney transplant.

Condition or disease Intervention/treatment Phase
Diabetes Kidney Transplantation Procedure: Islet Infusion Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Islet Transplantation in Type 1 Diabetic Recipients of Renal Allografts, Using the Edmonton Protocol
Study Start Date : September 2000
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: islet cell transplant Procedure: Islet Infusion

Primary Outcome Measures :
  1. independence from insulin injections with adequate control of blood glucose in subjects with Type 1 diabetes at one year post final transplant [ Time Frame: one year post final islet cell transplant ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Enrolling subjects must have Type 1 diabetes mellitus for more than 5 years, complicated by renal failure requiring a kidney transplant. The complicating situations are:

  1. Reduced awareness of hypoglycemia,
  2. Metabolic lability/instability,
  3. Despite efforts at optimal glucose control, progressive secondary complications of diabetes as defined by:

i) Retinopathy- ii) Nephropathy- or

iii) Neuropathy-

Exclusion Criteria:

  1. Severe co-existing cardiac disease, characterized by any one of these conditions:

    • recent myocardial infarction (within past 6 months), or
    • angiographic evidence of non-correctable coronary artery disease, or
    • evidence of ischemia on functional cardiac exam (•
  2. Active alcohol or substance abuse-includes cigarette smoking (

    • Failure to fulfill major work, school, or home responsibilities;
    • Drinking in situations that are physically dangerous, such as while driving a car or operating machinery;
    • Recurring alcohol-related legal problems, such as being arrested for driving under the influence of alcohol or for physically hurting someone while drunk;
    • Continued drinking despite having ongoing relationship problems that are caused or worsened by the effects of alcohol.
  3. Psychiatric disorder making the subject not a suitable candidate for transplantation,
  4. History of non-adherence to prescribed regimens
  5. Active infection including hepatitis C, hepatitis B, HIV, or TB (or under treatment for suspected TB)
  6. Any history of malignancy except squamous or basal skin cancer
  7. BMI > 26 kg/m2 or body weight > 70 kg for females and > 75kg for males at the screening visit. (An allowance for weight gain of up to +2 kg body weight is permitted between the screening visit and actual transplant. No transplant can be given to a female subject weighing > 72 kg or a male subject weighing > 77kg on the day of transplant. See Section 5.1 for minimum islet equivalent infusion requirements per recipient body weight.)
  8. C-peptide response to arginine stimulation (5 gm I.V.) (any C-peptide ≥ 0.3 ng/mL at 2, 3, 4, 5, 7 and 10 min post infusion)
  9. Inability to provide informed consent
  10. Age less than 18 or greater than 65 years
  11. Serum creatinine > 1.8 mg/dL, In addition, there must be no change in serum creatinine of > 0.4 mg/dl in the last 6 months.
  12. Baseline Hb < 10.5 gm/dL in women, or < 13 gm/dL in men
  13. Baseline LFT's outside of normal range with the exception of Gilberts Syndrome. n. Presence of gallstones (subjects may be eligible two weeks after a laparoscopic cholecystectomy ).

o. Hemangioma in liver on baseline ultrasound exam

p. Untreated proliferative retinopathy

q. Positive pregnancy test, intent for future pregnancy or male subjects' intent to procreate, failure to follow effective contraceptive measures, or presently breast feeding

r. Evidence of sensitization as determined by a general PRA with reactivity > 20%. t. Insulin requirement > 0.7 IU/kg/day

s. HbA1C > 12%

t. Inability to complete all scheduled visits during screening and post-transplant follow-up

u. Hyperlipidemia (fasting LDL cholesterol > 130 mg/dL, treated or untreated; and/or fasting triglycerides > 200 mg/dL).

v. Under treatment for a medical condition requiring chronic use of steroids at a dose > prednisone 5 mg/day w. Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT INR > 1.5 x. Addison's disease.y. EBV- negative subjects (use EBNA test for screening) to reduce potential risk of EBV infection for previously unexposed recipient.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00288977

Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Joslin Diabetes Center
Layout table for investigator information
Principal Investigator: Martha Pavlakis, MD Beth Israel Deaconess Medical Center, Joslin Diabetes Clinic
Layout table for additonal information
Responsible Party: Martha Pavlakis, Associate Professor of Medicine, Beth Israel Deaconess Medical Center Identifier: NCT00288977    
Other Study ID Numbers: 2001P001702
First Posted: February 9, 2006    Key Record Dates
Last Update Posted: March 16, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Martha Pavlakis, Beth Israel Deaconess Medical Center:
Islet Transplantation